Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;11(10):6227-6235.
doi: 10.4103/jfmpc.jfmpc_787_22. Epub 2022 Oct 31.

Blood pressure-lowering effect of telmisartan compared to losartan among mild to moderate essential hypertensive adult subjects: A meta-analysis

Kusum Kumari  1 , Mary Sunita Toppo  1 , Lakhan Majhi  1 , Amit Kumar  2
Affiliations

Blood pressure-lowering effect of telmisartan compared to losartan among mild to moderate essential hypertensive adult subjects: A meta-analysis

Kusum Kumari et al. J Family Med Prim Care. 2022 Oct.

Abstract

Objective: We conducted a meta-analysis in which the blood pressure (BP)-reducing effect of telmisartan was compared to losartan among hypertensive subjects and its association with ethnicity, age, and gender was investigated.

Materials and methods: PubMed, Google Scholar, and the Cochrane library were searched from inception to April 2021 to obtain relevant articles. Cochrane risk of bias assessment tool was used for assessment of bias risk. GRADE analysis was done for determining the certainty of evidence. Data was analyzed using Revman 5.4.2 software. The pooled mean difference with 95% confidence interval (CI) was computed using random-effects model. Heterogeneity was also assessed using meta-regression and subgroup analysis. This study has been registered in PROSPERO with registration no. CRD42021245122.

Results: Fifteen randomized controlled trials (RCTs) with 1926 subjects were selected from various countries. Both systolic BP (SBP) and diastolic BP (DBP) were found to be significantly reduced among telmisartan-treated groups (weighted mean difference [WMD] = 2.69, 95% CI: 1.38-4.00 and WMD = 1.26, 95% CI: 0.45-2.08 respectively). One subgroup analysis noted better reduction in both SBP and DBP among Asian population compared to Caucasians.

Conclusion: Telmisartan was found to be a better hypertensive drug compared to losartan in patients with mild to moderate hypertension. Its efficacy was higher in Asian population compared to Caucasian population.

Keywords: Blood Pressure; hypertension; losartan; meta-analysis; telmisartan.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Study selection process
Figure 2
Figure 2
Comparison of systolic blood pressure between telmisartan and losartan groups
Figure 3
Figure 3
Comparison of diastolic blood pressure between telmisartan and losartan groups
Figure 4
Figure 4
Comparison of adverse events between telmisartan and losartan groups
Figure 5
Figure 5
Meta-regression analysis
Figure 6
Figure 6
Risk of bias analysis. BP = blood pressure, CI = confidence interval, DBP = diastolic blood pressure, SBP = systolic blood pressure, WMD = weighted mean difference CI = confidence interval, MD = mean difference
See this image and copyright information in PMC

References

    1. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults:Report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA. 2014;311:507–20. - PubMed
    1. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16:223–37. - PMC - PubMed
    1. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control:A systematic analysis of population-based studies from 90 countries. Circulation. 2016;134:441–50. - PMC - PubMed
    1. Hasegawa H, Takano H, Narumi H, Ohtsuka M, Mizuguchi T, Namiki T, et al. Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients. Hypertens Res Off J Jpn Soc Hypertens. 2011;34:1179–84. - PubMed
    1. WHO. WHO Model List of Essential Medicine. Geneva: WHO; 2019. 21st List 2019.